Cargando…

Over-expression and characterization of NS3 and NS5A of Hepatitis C virus genotype 3a

BACKGROUND: Hepatitis C virus (HCV) is a common and leading cause for liver cirrhosis and hepatocellular carcinoma. Current therapies to treat HCV infection are shown to be partially effective and poorly tolerated. Therefore, ample efforts are underway to rationally design therapies targeting the HC...

Descripción completa

Detalles Bibliográficos
Autores principales: Anwar, Muhammad Ikram, Iqbal, Mazhar, Yousef, Mohammad S, Rahman, Moazur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842787/
https://www.ncbi.nlm.nih.gov/pubmed/24238670
http://dx.doi.org/10.1186/1475-2859-12-111
_version_ 1782292989483155456
author Anwar, Muhammad Ikram
Iqbal, Mazhar
Yousef, Mohammad S
Rahman, Moazur
author_facet Anwar, Muhammad Ikram
Iqbal, Mazhar
Yousef, Mohammad S
Rahman, Moazur
author_sort Anwar, Muhammad Ikram
collection PubMed
description BACKGROUND: Hepatitis C virus (HCV) is a common and leading cause for liver cirrhosis and hepatocellular carcinoma. Current therapies to treat HCV infection are shown to be partially effective and poorly tolerated. Therefore, ample efforts are underway to rationally design therapies targeting the HCV non-structural proteins. Most of the work carried out in this direction has been focusing mainly on HCV genotype 1. Two direct-acting antiviral agents (DAAs) Telaprevir and Boceprevir are being used against genotype 1a infection in combination therapy with interferon and ribavirin. Unfortunately these DAAs are not effective against genotype 3a. Considering the wide spread infection by HCV genotype 3a in developing countries especially South Asia, we have focused on the recombinant production of antiviral drug targets NS3 and NS5A from HCV genotype 3a. These protein targets are to be used for screening of inhibitors. RESULTS: High-level expression of NS3 and NS5A was achieved at 25°C, using ~1 and 0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG), respectively. Yields of the purified NS3 and NS5A were 4 and 1 mg per liter culture volume, respectively. Although similar amounts of purified NS3 were obtained at 25 and 14°C, specificity constant (K(cat)/K(m)) was somewhat higher at expression temperature of 25°C. Circular dichroism (CD) and Fourier-transform infrared (FT-IR) spectroscopy revealed that both NS3 and NS5A contain a mixture of alpha-helix and beta-sheet secondary structures. For NS3 protein, percentages of secondary structures were similar to the values predicted from homology modeling. CONCLUSIONS: NS3 and NS5A were over-expressed and using Nickel-affinity method both proteins were purified to ~ 95% purity. Yield of the purified NS3 obtained is four fold higher than previous reports. CD spectroscopy revealed that difference in activity of NS3 expressed at various temperatures is not related to changes in global structural features of the protein. Moreover, CD and FT-IR analysis showed that NS3 and NS5A contain both alpha-helical and beta-sheet structures and for NS5A, the proportion is almost equal. The production of NS3 and NS5A in milligram quantities will allow their characterization by biophysical and biochemical means that will help in designing new strategies to fight against HCV infection.
format Online
Article
Text
id pubmed-3842787
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38427872013-11-29 Over-expression and characterization of NS3 and NS5A of Hepatitis C virus genotype 3a Anwar, Muhammad Ikram Iqbal, Mazhar Yousef, Mohammad S Rahman, Moazur Microb Cell Fact Research BACKGROUND: Hepatitis C virus (HCV) is a common and leading cause for liver cirrhosis and hepatocellular carcinoma. Current therapies to treat HCV infection are shown to be partially effective and poorly tolerated. Therefore, ample efforts are underway to rationally design therapies targeting the HCV non-structural proteins. Most of the work carried out in this direction has been focusing mainly on HCV genotype 1. Two direct-acting antiviral agents (DAAs) Telaprevir and Boceprevir are being used against genotype 1a infection in combination therapy with interferon and ribavirin. Unfortunately these DAAs are not effective against genotype 3a. Considering the wide spread infection by HCV genotype 3a in developing countries especially South Asia, we have focused on the recombinant production of antiviral drug targets NS3 and NS5A from HCV genotype 3a. These protein targets are to be used for screening of inhibitors. RESULTS: High-level expression of NS3 and NS5A was achieved at 25°C, using ~1 and 0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG), respectively. Yields of the purified NS3 and NS5A were 4 and 1 mg per liter culture volume, respectively. Although similar amounts of purified NS3 were obtained at 25 and 14°C, specificity constant (K(cat)/K(m)) was somewhat higher at expression temperature of 25°C. Circular dichroism (CD) and Fourier-transform infrared (FT-IR) spectroscopy revealed that both NS3 and NS5A contain a mixture of alpha-helix and beta-sheet secondary structures. For NS3 protein, percentages of secondary structures were similar to the values predicted from homology modeling. CONCLUSIONS: NS3 and NS5A were over-expressed and using Nickel-affinity method both proteins were purified to ~ 95% purity. Yield of the purified NS3 obtained is four fold higher than previous reports. CD spectroscopy revealed that difference in activity of NS3 expressed at various temperatures is not related to changes in global structural features of the protein. Moreover, CD and FT-IR analysis showed that NS3 and NS5A contain both alpha-helical and beta-sheet structures and for NS5A, the proportion is almost equal. The production of NS3 and NS5A in milligram quantities will allow their characterization by biophysical and biochemical means that will help in designing new strategies to fight against HCV infection. BioMed Central 2013-11-16 /pmc/articles/PMC3842787/ /pubmed/24238670 http://dx.doi.org/10.1186/1475-2859-12-111 Text en Copyright © 2013 Anwar et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Anwar, Muhammad Ikram
Iqbal, Mazhar
Yousef, Mohammad S
Rahman, Moazur
Over-expression and characterization of NS3 and NS5A of Hepatitis C virus genotype 3a
title Over-expression and characterization of NS3 and NS5A of Hepatitis C virus genotype 3a
title_full Over-expression and characterization of NS3 and NS5A of Hepatitis C virus genotype 3a
title_fullStr Over-expression and characterization of NS3 and NS5A of Hepatitis C virus genotype 3a
title_full_unstemmed Over-expression and characterization of NS3 and NS5A of Hepatitis C virus genotype 3a
title_short Over-expression and characterization of NS3 and NS5A of Hepatitis C virus genotype 3a
title_sort over-expression and characterization of ns3 and ns5a of hepatitis c virus genotype 3a
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842787/
https://www.ncbi.nlm.nih.gov/pubmed/24238670
http://dx.doi.org/10.1186/1475-2859-12-111
work_keys_str_mv AT anwarmuhammadikram overexpressionandcharacterizationofns3andns5aofhepatitiscvirusgenotype3a
AT iqbalmazhar overexpressionandcharacterizationofns3andns5aofhepatitiscvirusgenotype3a
AT yousefmohammads overexpressionandcharacterizationofns3andns5aofhepatitiscvirusgenotype3a
AT rahmanmoazur overexpressionandcharacterizationofns3andns5aofhepatitiscvirusgenotype3a